![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Vistagen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system. Vistagen's pipeline includes six product candidates, including five ... Vistagen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system. Vistagen's pipeline includes six product candidates, including five clinical-stage investigational agents belonging to a new class of drugs known as pherines. Its portfolio includes PH94B, a novel neuroactive nasal spray with therapeutic potential in a wide range of indications involving anxiety or phobia. PH10, an odorless, fast-acting synthetic neurosteroid for neuropsychiatric indications involving depression. Show more
Registration-directed fasedienol PALISADE Phase 3 program for the acute treatment of social anxiety disorder progressing on track PALISADE-3 Phase 3 trial recently initiated; PALISADE-4 Phase 3...
U.S. index futures are falling in pre-market trading this Monday, amid anticipation for the Federal Reserve’s two-day monetary policy meeting, which begins today. As of 6:36 AM, Dow Jones...
Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological...
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological...
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological...
Vistagen (Nasdaq: VTGN), a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today...
PH15 nasal spray demonstrates statistically significant efficacy versus placebo and caffeine in a placebo-controlled Phase 2A pilot study in sleep-deprived participants PH15 was safe and...
Period β | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.04 | -1.2012012012 | 3.33 | 3.48 | 3.151 | 94776 | 3.28515872 | CS |
4 | -0.77 | -18.9655172414 | 4.06 | 4.06 | 3.151 | 131226 | 3.63501217 | CS |
12 | -2.01 | -37.9245283019 | 5.3 | 5.74 | 3.151 | 157347 | 4.45582026 | CS |
26 | -2.02 | -38.0414312618 | 5.31 | 5.86 | 3.151 | 234257 | 4.80554226 | CS |
52 | 1.56 | 90.1734104046 | 1.73 | 24.71 | 1.62 | 745833 | 7.5258606 | CS |
156 | -79.21 | -96.0121212121 | 82.5 | 106.5 | 1.62 | 3210578 | 12.95794607 | CS |
260 | -18.31 | -84.7685185185 | 21.6 | 106.5 | 1.62 | 2535638 | 21.76091008 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions